VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update

VivoSim Labs, Inc. (NASDAQ:VIVS) was the target of a large increase in short interest in April. As of April 30th, there was short interest totaling 52,788 shares, an increase of 88.7% from the April 15th total of 27,969 shares. Based on an average trading volume of 61,296 shares, the short-interest ratio is currently 0.9 days. Approximately 2.1% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded VivoSim Labs from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 7th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, VivoSim Labs presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On VivoSim Labs

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP bought a new stake in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned about 0.89% of VivoSim Labs at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.23% of the company’s stock.

VivoSim Labs Price Performance

Shares of VivoSim Labs stock traded down $0.03 during trading hours on Friday, hitting $1.29. 11,627 shares of the company’s stock traded hands, compared to its average volume of 51,620. VivoSim Labs has a 12-month low of $1.25 and a 12-month high of $5.30. The stock has a market capitalization of $3.36 million, a price-to-earnings ratio of -0.41 and a beta of 1.41. The company has a fifty day simple moving average of $1.58 and a 200-day simple moving average of $1.93.

VivoSim Labs (NASDAQ:VIVS) last announced its earnings results on Wednesday, February 11th. The company reported ($1.03) earnings per share (EPS) for the quarter. VivoSim Labs had a negative net margin of 861.27% and a negative return on equity of 15.51%. The business had revenue of $0.03 million for the quarter.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.